From NAFLD to NASH to fibrosis to HCC: Role of dendritic cell populations in the liver
Frank Tacke, Hiroyuki Yoneyama – 20 March 2013
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon‐alpha
Joachim Lupberger, François H.T. Duong, Isabel Fofana, Laetitia Zona, Fei Xiao, Christine Thumann, Sarah C. Durand, Patrick Pessaux, Mirjam B. Zeisel, Markus H. Heim, Thomas F. Baumert – 20 March 2013 – Interferon‐alpha (IFN‐α) exhibits its antiviral activity through signal transducer and activator of transcription protein (STAT) signaling and the expression of IFN response genes (IRGs). Viral infection has been shown to result in activation of epidermal growth factor receptor (EGFR)—a host cell entry factor used by several viruses, including hepatitis C virus.
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma
Manjeet Deshmukh, Yujin Hoshida – 20 March 2013
Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma
Eva Knüppel, Dominik Bettinger, Wulf Euringer, Robert Thimme, Martin Roessle, Hans Christian Spangenberg, Michael Schultheiss – 20 March 2013
Genetic basis of gall stone disease
Saumya Pandey – 20 March 2013
Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus–coinfected recipients versus human immunodeficiency virus–infected recipients without hepatitis C virus: Results from the national institutes of health mu
Ranjeeta Bahirwani, Burc Barin, Kim Olthoff, Peter Stock, Barbara Murphy, K. Rajender Reddy, for the Solid Organ Transplantation in HIV: Multi‐Site Study Investigators – 20 March 2013 – Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are both associated with chronic kidney disease (CKD), a major complication after orthotopic liver transplantation (OLT). The aim of this study was to assess predictors of post‐OLT CKD in HIV/HCV‐coinfected recipients versus HIV‐infected recipients without HCV (HIV/non‐HCV recipients).
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives
Riad Salem, Vincenzo Mazzaferro, Bruno Sangro – 19 March 2013
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives
Riad Salem, Vincenzo Mazzaferro, Bruno Sangro – 19 March 2013
Hepatocyte divalent metal‐ion transporter‐1 is dispensable for hepatic iron accumulation and non‐transferrin‐bound iron uptake in mice
Chia‐Yu Wang, Mitchell D. Knutson – 19 March 2013 – Divalent metal‐ion transporter‐1 (DMT1) is required for iron uptake by the intestine and developing erythroid cells. DMT1 is also present in the liver, where it has been implicated in the uptake of transferrin‐bound iron (TBI) and non‐transferrin‐bound iron (NTBI), which appears in the plasma during iron overload. To test the hypothesis that DMT1 is required for hepatic iron uptake, we examined mice with the Dmt1 gene selectively inactivated in hepatocytes (Dmt1liv/liv).
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma
Kai Wang, Ho Yeong Lim, Stephanie Shi, Jeeyun Lee, Shibing Deng, Tao Xie, Zhou Zhu, Yuli Wang, David Pocalyko, Wei Jennifer Yang, Paul A. Rejto, Mao Mao, Cheol‐Keun Park, Jiangchun Xu – 18 March 2013 – Cancer is a genetic disease with frequent somatic DNA alterations. Studying recurrent copy number aberrations (CNAs) in human cancers would enable the elucidation of disease mechanisms and the prioritization of candidate oncogenic drivers with causal roles in oncogenesis.